Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TLSI Stock Forecast 2025-2026
$7.06
Current Price
$352.75M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TLSI Price Targets
+126.6%
To High Target of $16.00
+55.8%
To Median Target of $11.00
+27.5%
To Low Target of $9.00
TLSI Price Momentum
+0.9%
1 Week Change
+60.8%
1 Month Change
+49.3%
1 Year Change
+40.9%
Year-to-Date Change
-3.6%
From 52W High of $7.32
+106.4%
From 52W Low of $3.42
📊 TOP ANALYST CALLS
Did TLSI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Trisalus is one of their latest high-conviction picks.
Latest TLSI Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, TLSI has a bullish consensus with a median price target of $11.00 (ranging from $9.00 to $16.00). The overall analyst rating is N/A (N/A/10). Currently trading at $7.06, the median forecast implies a 55.8% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Walsh at JonesTrading, projecting a 126.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TLSI Analyst Ratings
7
Buy
0
Hold
0
Sell
TLSI Price Target Range
Low
$9.00
Average
$11.00
High
$16.00
Current: $7.06
Latest TLSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TLSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 28, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $11.00 |
| Feb 13, 2025 | Lake Street | Buy | Initiates | $10.00 | |
| Jan 24, 2025 | Roth MKM | Jason Wittes | Buy | Reiterates | $11.00 |
| Dec 17, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Initiates | $10.00 |
| Nov 15, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $11.00 |
| Nov 11, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $11.00 |
| Oct 25, 2024 | Northland Capital Markets | Carl Byrnes | Outperform | Initiates | $12.50 |
| Sep 16, 2024 | Oppenheimer | Suraj Kalia | Outperform | Initiates | $10.00 |
| Jun 27, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $12.00 |
| May 30, 2024 | Canaccord Genuity | William Plovanic | Buy | Initiates | $12.00 |
| May 10, 2024 | JonesTrading | Justin Walsh | Buy | Initiates | $16.00 |
TriSalus Life Sciences Inc. (TLSI) Competitors
The following stocks are similar to Trisalus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TriSalus Life Sciences Inc. (TLSI) Financial Data
TriSalus Life Sciences Inc. has a market capitalization of $352.75M with a P/E ratio of 0.1x. The company generates $40.21M in trailing twelve-month revenue with a -98.4% profit margin.
Revenue growth is +57.4% quarter-over-quarter, while maintaining an operating margin of -77.9% and return on equity of +128.3%.
Valuation Metrics
Market Cap
$352.75M
Enterprise Value
$364.19M
P/E Ratio
0.1x
PEG Ratio
0.0x
Price/Sales
8.8x
Growth & Margins
Revenue Growth (YoY)
+57.4%
Gross Margin
+83.5%
Operating Margin
-77.9%
Net Margin
-98.4%
EPS Growth
+57.4%
Financial Health
Cash/Price Ratio
+6.4%
Current Ratio
3.1x
Debt/Equity
-1.3x
ROE
+128.3%
ROA
-61.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
TriSalus Life Sciences Inc. (TLSI) Business Model
About TriSalus Life Sciences Inc.
What They Do
Develops innovative cancer therapies using unique technologies.
Business Model
TriSalus Life Sciences generates revenue by developing and commercializing advanced therapies for cancer treatment, particularly targeting solid tumors. The company utilizes its proprietary Pressure-Enabled Drug Delivery (PEDD) technology to enhance drug efficacy and distribution, collaborating with research institutions and healthcare providers to facilitate clinical trials and eventual market availability.
Additional Information
As a participant in the biotechnology industry, TriSalus Life Sciences aims to improve patient outcomes in cancer care through its innovative approaches. The company's focus on addressing vascular perfusion and immune suppression in tumor environments positions it as a key player in advancing oncological therapeutic strategies.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
110
CEO
Ms. Mary T. Szela B.S.N., M.B.A.
Country
United States
IPO Year
2021
Website
trisaluslifesci.comTriSalus Life Sciences Inc. (TLSI) Latest News & Analysis
Latest News
Quick Summary
TriSalus Life Sciences (Nasdaq: TLSI) will host a virtual KOL event on December 15, 2025, featuring Dr. Juan C. Camacho to discuss unmet needs in solid tumor treatment.
Why It Matters
The KOL event indicates potential advancements in oncology treatment, which could influence TriSalus's market position and investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
TriSalus Life Sciences launched the TriNav® XP Infusion System, enhancing drug delivery for solid tumor treatments, building on its successful TriNav platform.
Why It Matters
TriSalus Life Sciences' launch of the TriNav® XP Infusion System enhances drug delivery for cancer treatments, potentially increasing market share and revenue, signaling growth prospects for investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
TriSalus Life Sciences, Inc. will hold its Q3 2025 Earnings Call on November 13, 2025, at 4:30 PM EST, featuring CEO Mary Szela and CFO David Patience among others.
Why It Matters
TriSalus Life Sciences' Q3 2025 earnings call indicates financial performance insights, key strategies, and market positioning which can influence stock valuations and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
25 days ago
Quick Summary
TriSalus Life Sciences (Nasdaq: TLSI) reported strong commercial performance for Q3 2025, focusing on its immunotherapeutic and novel delivery technology for solid tumors.
Why It Matters
TriSalus Life Sciences reported strong commercial performance, indicating potential revenue growth and increased investor confidence in its innovative cancer treatment technologies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
TriSalus Life Sciences, Inc. (TLSI) reported a quarterly loss of $0.96 per share, missing the Zacks Consensus Estimate of a $0.17 loss, compared to a loss of $0.40 per share a year earlier.
Why It Matters
TriSalus Life Sciences' larger-than-expected loss signals financial struggles and may impact investor confidence, stock performance, and future funding prospects.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
TriSalus Life Sciences, Inc. hosted a KOL event discussing pressure-enabled drug delivery and advancements in uterine fibroid embolization on November 12, 2025.
Why It Matters
TriSalus Life Sciences' focus on innovative drug delivery methods and uterine fibroid treatment could signal potential growth and market interest, influencing stock performance and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About TLSI Stock
What is TriSalus Life Sciences Inc.'s (TLSI) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, TriSalus Life Sciences Inc. (TLSI) has a median price target of $11.00. The highest price target is $16.00 and the lowest is $9.00.
Is TLSI stock a good investment in 2026?
According to current analyst ratings, TLSI has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TLSI stock?
Wall Street analysts predict TLSI stock could reach $11.00 in the next 12 months. This represents a 55.8% increase from the current price of $7.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is TriSalus Life Sciences Inc.'s business model?
TriSalus Life Sciences generates revenue by developing and commercializing advanced therapies for cancer treatment, particularly targeting solid tumors. The company utilizes its proprietary Pressure-Enabled Drug Delivery (PEDD) technology to enhance drug efficacy and distribution, collaborating with research institutions and healthcare providers to facilitate clinical trials and eventual market availability.
What is the highest forecasted price for TLSI TriSalus Life Sciences Inc.?
The highest price target for TLSI is $16.00 from Justin Walsh at JonesTrading, which represents a 126.6% increase from the current price of $7.06.
What is the lowest forecasted price for TLSI TriSalus Life Sciences Inc.?
The lowest price target for TLSI is $9.00 from at , which represents a 27.5% increase from the current price of $7.06.
What is the overall TLSI consensus from analysts for TriSalus Life Sciences Inc.?
The overall analyst consensus for TLSI is bullish. Out of 7 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are TLSI stock price projections?
Stock price projections, including those for TriSalus Life Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 4:08 AM UTC